CT102

  • A DC-based immunotherapy targeting metastatic cancers with a short-cut process. Metastasis leads mortality in approximately 90% of cancer patients but current cancer treatments still neglect the sight to suppress metastasis. We have developed a time-saving process to generate DC to treat metastatic patients. This product will significantly reduce therapy price and effectively eliminate metastasis. We will initiate clinical trials in 2019.